Renal impairment: A risk factor for ischemic heart disease

Current Opinion in Pharmacology

Volumn 6, Issue 2, 2006, Pages 221-225

  Zoccali, Carmine ^a  

^a CNR IBIM Clinical Epidemiology of Renal Diseases and Hypertension   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; EZETIMIBE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; VALSARTAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMMUNITY; CORONARY STENT; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; ESSENTIAL HYPERTENSION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION;

CORONARY DISEASE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; RISK FACTORS;

EID: 33644833881     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.11.007     Document Type: Review

References (48)

1. A. Lindner B. Charra D.J. Sherrard B.H. Scribner Accelerated atherosclerosis in prolonged maintenance hemodialysis N Engl J Med 290 1974 697-701
2. C. Zoccali F. Mallamaci G. Tripepi Traditional and emerging cardiovascular risk factors in end-stage renal disease Kidney Int Suppl 85 2003 S105-S110
3. V. Menon A. Gul M.J. Sarnak Cardiovascular risk factors in chronic kidney disease Kidney Int 68 2005 1413-1418
4. K. Amann C. Ritz M. Adamczak E. Ritz Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 18 2003 631-640
5. M.J. Sarnak A.S. Levey A.C. Schoolwerth J. Coresh B. Culleton L.L. Hamm P.A. McCullough B.L. Kasiske E. Kelepouris M.J. Klag et. al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2003 2154-2169
6. C. Zoccali Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention Nephrol Dial Transplant 17 Suppl 11 2002 50-54
7. R.N. Foley P.S. Parfrey M.J. Sarnak Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 1998 S16-S23
8. K/DOQI Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients Am J Kidney Dis 45 2005 S1-153
9. B.F. Culleton M.G. Larson P.W. Wilson J.C. Evans P.S. Parfrey D. Levy Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214-2219
10. A.X. Garg W.F. Clark R.B. Haynes A.A. House Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I Kidney Int 61 2002 1486-1494
11. P. Muntner J. He L. Hamm C. Loria P.K. Whelton Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States J Am Soc Nephrol 13 2002 745-753
12. R.M. Henry P.J. Kostense G. Bos J.M. Dekker G. Nijpels R.J. Heine L.M. Bouter C.D. Stehouwer Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study Kidney Int 62 2002 1402-1407
13. G. Manjunath H. Tighiouart H. Ibrahim B. MacLeod D.N. Salem J.L. Griffith J. Coresh A.S. Levey M.J. Sarnak Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J Am Coll Cardiol 41 2003 47-55
14. D.E. Weiner H. Tighiouart M.G. Amin P.C. Stark B. MacLeod J.L. Griffith D.N. Salem A.S. Levey M.J. Sarnak Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies J Am Soc Nephrol 15 2004 1307-1315
15. A.S. Go G.M. Chertow D. Fan C.E. McCulloch C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296-1305
16. L.M. Ruilope A. Salvetti K. Jamerson L. Hansson I. Warnold H. Wedel A. Zanchetti Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study J Am Soc Nephrol 12 2001 218-225
17. S.G. Wannamethee A.G. Shaper I.J. Perry Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke Stroke 28 1997 557-563
18. K. Klausen K. Borch-Johnsen B. Feldt-Rasmussen G. Jensen P. Clausen H. Scharling M. Appleyard J.S. Jensen Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes Circulation 110 2004 32-35
19. G. Schillaci G. Reboldi P. Verdecchia High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension Arch Intern Med 161 2001 886-891
20. S.M. Hailpern H.W. Cohen M.H. Alderman Renal dysfunction and ischemic heart disease mortality in a hypertensive population J Hypertens 23 2005 1809-1816
21. C.A. Herzog J.Z. Ma A.J. Collins Poor long-term survival after acute myocardial infarction among patients on long-term dialysis N Engl J Med 339 1998 799-805
22. R.S. Wright G.S. Reeder C.A. Herzog R.C. Albright B.A. Williams D.L. Dvorak W.L. Miller J.G. Murphy S.L. Kopecky A.S. Jaffe Acute myocardial infarction and renal dysfunction: A high-risk combination Ann Intern Med 137 2002 563-570
23. J.L. Januzzi C.P. Cannon P.M. DiBattiste S. Murphy W. Weintraub E. Braunwald Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial) Am J Cardiol 90 2002 1246-1249
24. C.M. Gibson D.S. Pinto S.A. Murphy D.A. Morrow H.P. Hobbach S.D. Wiviott R.P. Giugliano C.P. Cannon E.M. Antman E. Braunwald Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality J Am Coll Cardiol 42 2003 1535-1543
25. N.S. Anavekar J.J. McMurray E.J. Velazquez S.D. Solomon L. Kober J.L. Rouleau H.D. White R. Nordlander A. Maggioni K. Dickstein et. al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285-1295
26. United States Renal Data System: USRDS 1999 Annual Report. National Institute of Diabetes and Digestive and Kidney Diseases, 1999 (http://www.usrds.org/adr_1999.htm).
27. N. Freemantle J. Cleland P. Young J. Mason J. Harrison β Blockade after myocardial infarction: Systematic review and meta regression analysis BMJ 318 1999 1730-1737
28. G. Cice L. Ferrara B.A. Di P.E. Russo G. Marinelli F. Pavese A. Iacono Dilated cardiomyopathy in dialysis patients - beneficial effects of carvedilol: A double-blind, placebo-controlled trial J Am Coll Cardiol 37 2001 407-411
29. G. Cice L. Ferrara A. D'Andrea S. D'Isa B.A. Di A. Cittadini P.E. Russo P. Golino R. Calabro Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial J Am Coll Cardiol 41 2003 1438-1444
30. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994. 308:81-106.
31. J.S. Fernandez B.T. Sadaniantz A. Sadaniantz Review of antithrombotic agents used for acute coronary syndromes in renal patients Am J Kidney Dis 42 2003 446-455
32. C. Baigent M. Landray C. Leaper P. Altmann J. Armitage A. Baxter H.S. Cairns R. Collins R.N. Foley V. Frighi et. al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease Am J Kidney Dis 45 2005 473-484
33. S. Yusuf F. Zhao S.R. Mehta S. Chrolavicius G. Tognoni K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494-502
34. M.P. Tokmakova H. Skali S. Kenchaiah E. Braunwald J.L. Rouleau M. Packer G.M. Chertow L.A. Moye M.A. Pfeffer S.D. Solomon Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival And Ventricular Enlargement (SAVE) study Circulation 110 2004 3667-3673
35. J.F. Mann H.C. Gerstein J. Pogue J. Bosch S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629-636
36. N. Nakao A. Yoshimura H. Morita M. Takada T. Kayano T. Ideura Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial 3 Lancet 361 2003 117-124
37. M. Tonelli C. Isles G.C. Curhan A. Tonkin M.A. Pfeffer J. Shepherd F.M. Sacks C. Furberg S.M. Cobbe J. Simes et. al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557-1563
38. M. Tonelli C. Isles T. Craven A. Tonkin M.A. Pfeffer J. Shepherd F.M. Sacks C. Furberg S.M. Cobbe J. Simes et. al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease Circulation 112 2005 171-178
39. P.S. Sever B. Dahlof N.R. Poulter H. Wedel G. Beevers M. Caulfield R. Collins S.E. Kjeldsen A. Kristinsson G.T. McInnes et. al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial Lancet 361 2003 1149-1158
40. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7-22
41. H. Holdaas B. Fellstrom A.G. Jardine G. Nyberg C. Gronhagen-Riska S. Madsen H.H. Neumayer E. Cole B. Maes P. Ambuhl et. al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation Nephrol Dial Transplant 20 2005 974-980
42. C. Wanner V. Krane W. Marz M. Olschewski J.F. Mann G. Ruf E. Ritz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238-248
43. D.N. Juurlink M.M. Mamdani D.S. Lee A. Kopp P.C. Austin A. Laupacis D.A. Redelmeier Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543-551
44. B. Pitt W. Remme F. Zannad J. Neaton F. Martinez B. Roniker R. Bittman S. Hurley J. Kleiman M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309-1321
45. C. Stigant M. Izadnegahdar A. Levin C.E. Buller K.H. Humphries Outcomes after percutaneous coronary interventions in patients with CKD: Improved outcome in the stenting era Am J Kidney Dis 45 2005 1002-1009
46. I. Iakovou T. Schmidt E. Bonizzoni L. Ge G.M. Sangiorgi G. Stankovic F. Airoldi A. Chieffo M. Montorfano M. Carlino et. al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126-2130
47. T.M. Sundt Technology insight: Randomized trials of off-pump versus on-pump coronary artery bypass surgery Nat Clin Pract Cardiovasc Med 2 2005 261-268
48. G.J. Moore A. Pfister G.D. Trachiotis Outcomes for off-pump coronary artery bypass grafting in high-risk groups: A historical perspective Heart Surg Forum 8 2005 E19-E22